※Findings from A. Jazayeri and Colleagues Update Understanding of Adenosine Therapy (Structurally Enabled Discovery of Adenosine A Receptor Antagonists)
17 February 2017
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Drugs and Therapies - Adenosine Therapy.
According to news reporting from Welwyn Garden City, United Kingdom, by NewsRx journalists, research stated, "Over the past decade there has been a revolution in the field of G protein-coupled receptor (GPCR) structural biology.
Many years of innovative research from different areas have come together to fuel this significant change in the fortunes of this field, which for many years was characterized by the paucity of high-resolution structures."
The news correspondents obtained a quote from the research, "The determination to succeed has been in part due to the recognized importance of these proteins as drug targets, and although the pharmaceutical industry has been focusing on these receptors,
it can be justifiably argued and demonstrated that many of the approved and commercially successful GPCR drugs can be significantly improved to increase efficacy and/or reduce undesired side effects.
In addition, many validated targets in this class remain to be drugged. It is widely recognized that application of structure-based drug design approaches can help medicinal chemists a long way toward discovering better drugs.
The achievement of structural biologists in providing high-resolution insight is beginning to transform drug discovery efforts, and there are a number of GPCR drugs that have been discovered by use of structural information that are in clinical development."
According to the news reporters, the research concluded:
"This review aims to highlight the key developments that have brought success to GPCR structure resolution efforts and exemplify the practical application of structural information for the discovery of adenosine A receptor antagonists that have potential to treat multiple conditions."
For more information on this research see: Structurally Enabled Discovery of Adenosine A Receptor Antagonists.
※Findings from A. Jazayeri and Colleagues Update Understanding of Adenosine Therapy (Structurally Enabled Discovery of Adenosine A Receptor Antagonists)
17 February 2017
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Drugs and Therapies - Adenosine Therapy.
According to news reporting from Welwyn Garden City, United Kingdom, by NewsRx journalists, research stated, "Over the past decade there has been a revolution in the field of G protein-coupled receptor (GPCR) structural biology.
Many years of innovative research from different areas have come together to fuel this significant change in the fortunes of this field, which for many years was characterized by the paucity of high-resolution structures."
The news correspondents obtained a quote from the research, "The determination to succeed has been in part due to the recognized importance of these proteins as drug targets, and although the pharmaceutical industry has been focusing on these receptors,
it can be justifiably argued and demonstrated that many of the approved and commercially successful GPCR drugs can be significantly improved to increase efficacy and/or reduce undesired side effects.
In addition, many validated targets in this class remain to be drugged. It is widely recognized that application of structure-based drug design approaches can help medicinal chemists a long way toward discovering better drugs.
The achievement of structural biologists in providing high-resolution insight is beginning to transform drug discovery efforts, and there are a number of GPCR drugs that have been discovered by use of structural information that are in clinical development."
According to the news reporters, the research concluded:
"This review aims to highlight the key developments that have brought success to GPCR structure resolution efforts and exemplify the practical application of structural information for the discovery of adenosine A receptor antagonists that have potential to treat multiple conditions."
For more information on this research see: Structurally Enabled Discovery of Adenosine A Receptor Antagonists.